Dave Inc./DE
Dave Reports Third Quarter 2026 Financial Results
Q3 Revenue Growth Accelerates to 31% Y/Y to $198 Million, Driven by Record New Member Acquisition as well as Continued MTM Growth and ARPU Expansion
Source
From SEC EDGAR
132 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
HMH Holding Inc
HMH Holding Inc. Announces Third Quarter 2026 Results
American Homes 4 Rent, L.P.
American Homes 4 Rent, L.P.
AMH Reports Third Quarter 2026 Financial and Operating Results
Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues
Ascent Industries Co.
Ascent Industries Reports Third Quarter 2026 Results; Year-Over-Year Net Sales Increase 37.8%, Including 26.3% Growth in Sales Excluding the Midwest Graphic Sales Acquisition; Adjusted EBITDA Improves by $2.1 Million
Sequentially, net sales increased 5.7%, gross profit increased 28.3% and
3d Systems Corp
3D Systems Reports Third Quarter 2026 Financial Results
Pursuit Attractions & Hospitality, Inc.
Pursuit Attractions & Hospitality, Inc.
PURSUIT REPORTS RECORD THIRD QUARTER 2026 RESULTS AND REAFFIRMS FULL YEAR ADJUSTED EBITDA GUIDANCE MIDPOINT
Mativ Holdings, Inc.
Mativ Announces Third Quarter 2026 Results
Alpha Teknova, Inc.
Teknova Reports Third Quarter 2026 Financial Results
Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year
Klaviyo, Inc.
Klaviyo Delivers Solid Q3 with Enterprise Growth, Multi-Product Strength, and Agent Traction
Third quarter revenue of $387.2 million, representing 25% year-over-year growth
Corpay, Inc.
Corpay Reports Third Quarter Financial Results
18% revenue growth, 11% organic revenue growth, and 32% adjusted EPS growth1
ThredUp Inc.
ThredUp Announces Third Quarter 2026 Results
•Quarterly revenue of $88.2 million, representing an increase of 7% year-over-year
Dutch Bros Inc.
Dutch Bros Inc. Reports Third Quarter 2026 Financial Results
Achieves 30% Revenue Growth Year-Over-Year
Dianthus Therapeutics, Inc. /DE/
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in…
Rayonier, L.P.